Andrew Norris
Chief Scientific Officer BCN Biosciences
Seminars
Wednesday 17th September 2025
Panel Discussion: Reducing Non-Responsiveness of RAS-Targeted Therapies by Delving into Mutation & Tissue Specific Impacts to Improve Drug Efficacy
1:00 pm
- Â Uncovering the current status and unmet medical needs for patients with RAS-driven cancers, what cancers need more improved response rates?
- What genomic features predict poor response and outcomes for RAS-targeting therapies?
- How do you successfully overcome or delay resistance to RAS-targeting therapies?
Thursday 18th September 2025
Improving Therapeutic Efficacy by Targeting the MAPK Pathway to Disrupt Tumor Growth & Reduce Oncogenesis
4:00 pm
- How to target specific MAPK substrates that are critical for tumor growth without disrupting broader cellular functions
- How does targeting upstream and downstream regulators of RAS signaling enhance drug efficacy?
- Addressing how alternative signaling pathways, particularly the PI3K/AKT pathway, contribute to resistance against MAPK-targeted therapies
